摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

氰基乙酸N-羟基丁二酰亚胺酯 | 56657-76-2

中文名称
氰基乙酸N-羟基丁二酰亚胺酯
中文别名
乙酸,2-氰基-,2,5-二氧代-1-吡咯烷基酯;氰基乙酸-N-羟基丁二酰亚胺酯
英文名称
succinimidyl cyanoacetate
英文别名
3-[(2,5-dioxopyrrolidin-1-yl)oxy]-3-oxopropanenitrile;2,5-dioxopyrrolidin-1-yl 2-cyanoacetate;cyanoacetic acid N-hydroxysuccinimide ester;(2,5-dioxopyrrolidin-1-yl) 2-cyanoacetate
氰基乙酸N-羟基丁二酰亚胺酯化学式
CAS
56657-76-2
化学式
C7H6N2O4
mdl
MFCD00798802
分子量
182.136
InChiKey
OZLIBRFWDOSHRS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    336.1±44.0 °C(Predicted)
  • 密度:
    1.46±0.1 g/cm3(Predicted)
  • 溶解度:
    二甲基亚砜(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.428
  • 拓扑面积:
    87.5
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2926909090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302

SDS

SDS:3ee861234f6010e3168582e2f524d4da
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Cyanoacetic acid-osu
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Cyanoacetic acid-osu
CAS number: 56657-76-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6N2O4
Molecular weight: 182.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

乙酸N-羟基丁二酰亚胺酯用作医药中间体。它主要用于合成取代吡啶嘧啶胺,这是一种选择性的Janus激酶抑制剂,可用于治疗自身免疫性疾病和预防器官移植后的排斥反应。

反应信息

  • 作为反应物:
    描述:
    3-(2-aminoethylthio)rifamycin SV 、 氰基乙酸N-羟基丁二酰亚胺酯 在 phosphate buffer 作用下, 以 四氢呋喃 为溶剂, 反应 24.0h, 生成 3-<(2'-cyanoethylamido)ethylthio>rifamycin SV
    参考文献:
    名称:
    Bartolucci; Cellai; Di Filippo, Il Farmaco, 1992, vol. 47, # 11, p. 1367 - 1383
    摘要:
    DOI:
  • 作为产物:
    描述:
    N-羟基丁二酰亚胺氰乙酸N,N'-二环己基碳二亚胺 作用下, 以 四氢呋喃 为溶剂, 以73.5 %的产率得到氰基乙酸N-羟基丁二酰亚胺酯
    参考文献:
    名称:
    一种托法替布中间体的制备方法
    摘要:
    本发明属于医药化工技术领域,具体涉及一种托法替布中间体的制备方法。制备方法包括如下步骤:N‑羟基丁二酰亚胺和氰基乙酸在缩合剂条件下反应形成氰基乙酸‑N‑羟基丁二酰亚胺酯,式3化合物为托法替布中间体。缩合剂包括N,N’‑羰基二咪唑、二环己基碳二亚胺、1‑乙基‑(3‑二甲基氨基丙基)碳酰二亚胺盐酸盐中的至少一种。本发明提供了一种新的合成托法替布中间体的方法,收率较佳,且中间体有益于托法替布原料药的制备。
    公开号:
    CN117534603A
  • 作为试剂:
    参考文献:
    名称:
    [EN] OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS
    [FR] RESOLUTION OPTIQUE DE (1-BENZYL-4-METHYLPIPERIDINE-3-YLE) METHYLAMINE ET SON UTILISATION POUR LA PREPARATION DE DERIVES DE PYRROLO 2,3-PYRIMIDINE UTILISES COMME INHIBITEURS DE PROTEINES KINASE
    摘要:
    一种用于分离含有公式(I)结构的化合物的对映异构体的方法,其中R4或R5可能包含一个或多个不对称中心,通过将含有该公式结构的化合物的对映异构体的混合物与一个具有定义的立体特异性的分离剂混合在溶剂中,形成溶液,所述分离剂能够与至少一个但不是全部的对映异构体结合形成沉淀,其中包含所述至少一个对映异构体的立体特异形式,并收集沉淀并纯化它,或收集所述溶液并重新结晶所述溶液中所含的其他对映异构体并分离所述溶液中所含的所述对映异构体。
    公开号:
    WO2002096909A1
点击查看最新优质反应信息

文献信息

  • [EN] DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK<br/>[FR] COMPOSÉS DE DIHYDROPYRROLONAPHTYRIDINONE COMME INHIBITEURS DE JAK
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2010144486A1
    公开(公告)日:2010-12-16
    Disclosed are JAK inhibitors of formula (I) where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
    揭示了式(I)的JAK抑制剂,其中G1、R1、R2、R3、R4、R5、R6和R7在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品,制备这些化合物的方法和材料,以及使用这些化合物治疗涉及免疫系统和炎症的疾病、紊乱和症状的方法,包括类风湿关节炎、血液恶性肿瘤、上皮癌(即癌症)和其他与JAK相关的疾病、紊乱或症状。
  • [EN] FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE CONDENSÉS UTILISÉS EN TANT QU'INHIBITEURS DE JAK
    申请人:ALMIRALL SA
    公开号:WO2017220431A1
    公开(公告)日:2017-12-28
    Novel fused pyrazole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    公开了式(I)的新型融合吡唑生物;以及它们的制备方法,包含它们的药物组合物以及它们作为Janus激酶(JAK)抑制剂在治疗中的用途。
  • MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
    申请人:Combs Andrew Paul
    公开号:US20090286778A1
    公开(公告)日:2009-11-19
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及以下化学式I的大环化合物: 或其药用可接受盐或季盐,其中所述成员在此提供,并且它们的组成物和使用方法,这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用,例如炎症和自身免疫性疾病以及癌症。
  • [EN] PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDIN-2-YLE UTILISÉS COMME INHIBITEURS DE JAK
    申请人:ALMIRALL SA
    公开号:WO2015086693A1
    公开(公告)日:2015-06-18
    New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    新的吡唑吡啶-2-基衍生物被披露;以及它们的制备方法,包含它们的药物组合物以及它们作为Janus激酶(JAK)抑制剂在治疗中的用途。
  • [EN] IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES<br/>[FR] IMIDAZOPYRROLOPYRIDINE EN TANT QU'INHIBITEURS DE LA FAMILLE JAK DE KINASES
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2018112382A1
    公开(公告)日:2018-06-21
    2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile化合物,含有它们的药物组合物,制备它们的方法,以及使用它们的方法,包括用于治疗由JAK介导的疾病状态、紊乱和疾病,如炎症性肠病的方法。
查看更多

同类化合物

(5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基酰肼盐酸盐 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG6-丙酸 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-四聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-六聚乙二醇-羧酸 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-八聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式草酸双(-3,8-二氮杂双环[4.2.0]辛烷-8-羧酸叔丁酯) 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式4-氟吡咯烷酮-3-醇盐酸盐 顺式3,4-二羟基吡咯烷盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-5-甲基-1H-六氢吡咯并[3,4-b]吡咯二盐酸盐 顺式-5-氧代六氢环戊二烯并[c]吡咯-2(1H)-羧酸叔丁酯 顺式-5-乙氧羰基-1H-六氢吡咯并[3,4-B]吡咯盐酸盐 顺式-5-(碘甲基)-4-苯基-2-吡咯烷酮 顺式-5-(碘甲基)-4-甲基-2-吡咯烷酮 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-1-甲基六氢吡咯并[3,4-b]吡咯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁